Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group
-
- Sanne Noort
- Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital Rotterdam, Rotterdam, The Netherlands;
-
- Martin Zimmermann
- Department of Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany;
-
- Dirk Reinhardt
- Acute Myeloid Leukemia-Berlin-Frankfurt-Münster Study Group, Pediatric Hematology and Oncology, Essen, Germany;
-
- Wendy Cuccuini
- Department of Cytogenetics, Saint Louis Hospital, Paris, France;
-
- Martina Pigazzi
- Women and Children’s Health, Hematology-Oncology Laboratory, University of Padova, Padova, Italy;
-
- Jenny Smith
- Fred Hutchinson Cancer Research Center, Seattle, WA;
-
- Rhonda E. Ries
- Fred Hutchinson Cancer Research Center, Seattle, WA;
-
- Todd A. Alonzo
- Children's Oncology Group, Monrovia, CA;
-
- Betsy Hirsch
- Children's Oncology Group, Monrovia, CA;
-
- Daisuke Tomizawa
- Division of Leukemia and Lymphoma, Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan;
-
- Franco Locatelli
- Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Pediatrico Bambino Gesù, Rome, Italy;
-
- Tanja A. Gruber
- Department of Oncology and
-
- Susana Raimondi
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN;
-
- Edwin Sonneveld
- Dutch Childhood Oncology Group, The Hague, The Netherlands;
-
- Daniel K. Cheuk
- Department of Pediatrics and Adolescent Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong;
-
- Michael Dworzak
- Department of Pediatrics, Children’s Cancer Research Institute and St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria;
-
- Jan Stary
- Czech Pediatric Hematology/Oncology, University Hospital Motol and Charles University, Prague, Czech Republic;
-
- Jonas Abrahamsson
- Nordic Society for Pediatric Hematology and Oncology, Department of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
-
- Nira Arad-Cohen
- Pediatric Hemato-Oncology Department, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel;
-
- Malgorzata Czogala
- Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland;
-
- Barbara De Moerloose
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium;
-
- Henrik Hasle
- Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark;
-
- Soheil Meshinchi
- Fred Hutchinson Cancer Research Center, Seattle, WA;
-
- Marry van den Heuvel-Eibrink
- Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital Rotterdam, Rotterdam, The Netherlands;
-
- C. Michel Zwaan
- Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital Rotterdam, Rotterdam, The Netherlands;
抄録
<jats:title>Key Points</jats:title> <jats:p>t(16;21) translocations in AML comprise t(16;21)(p11;q22) (FUS-ERG) as well as t(16;21)(q24;q22) (RUNX1-CBFA2T3). Survival in pediatric AML with FUS-ERG is poor, whereas survival in RUNX1-CBFA2T3 is similar to other core-binding factor leukemias.</jats:p>
収録刊行物
-
- Blood
-
Blood 132 (15), 1584-1592, 2018-10-11
American Society of Hematology
